What You Should Know
- Boehringer Ingelheim and Click Therapeutics have restructured their commercialization agreement for CT-155.
- Boehringer is transferring all commercial and marketing rights to Click, backed by a $50M Series D strategic investment and undisclosed dedicated commercial funding.
The Clinical Moat: Conquering ‘Negative’ Symptoms
To understand why Boehringer is willing to pour $50M into Click’s commercial engine, you have to look at the massive clinical unmet need CT-155 is targeting.
When people think of schizophrenia, they typically think of “positive” symptoms: hallucinations and delusions. Standard antipsychotic medications are relatively effective at managing these. However, standard drugs largely fail to treat the “negative” symptoms: the crushing lack of motivation, emotional flatness, and severe social withdrawal. Currently, there are zero FDA-approved treatments indicated specifically for these negative symptoms.
CT-155, which received FDA Breakthrough Device Designation in 2024, attacks this exact blind spot through interactive, software-based psychosocial interventions. And the data proves it works. In the Phase III CONVOKE study, CT-155 drove a 6.8-point improvement in negative symptom severity at 16 weeks, representing a massive 62% relative improvement over the digital control app. Furthermore, it did this with an adverse event profile (8.3%) that was actually lower than the control arm (13.4%).
“Boehringer Ingelheim’s selection of Click to deliver CT-155 to patients is powerful validation of our vision and the capabilities we have spent over a decade building,” noted David Benshoof Klein, CEO and founder of Click Therapeutics.
